A CAR-T for Patients Who Already Failed CAR-T

PMB-CT01 reads a completely different nametag: BAFF-R (B-cell activating factor receptor). It's a protein found almost exclusively on B cells, and it plays a key role in keeping those cells alive. By switching targets, PeproMene sidesteps the most common escape route cancer uses to dodge CD19-directed treatments. It's like changing the locks after a burglar already copied your keys.

The Scientific Pedigree

PeproMene Bio isn't exactly a garage startup, though it is small. Founded around 2016 in Irvine, California, the company licensed its core BAFF-R technology from City of Hope in 2017. The antibody at the heart of PMB-CT01 was discovered in the lab of Dr. Larry Kwak, who did foundational work at MD Anderson Cancer Center and City of Hope. Kwak serves as the company's scientific founder.

Funding has been modest by biotech standards: roughly $44 million to $52 million raised in total, including a $40.2 million Series B in 2018 and an $11 million investment in December 2024 from the Institute for Follicular Lymphoma Innovation. That's not Moderna money, but it's enough to get through early clinical work.

The "Yeah, But" Section

Let's be honest about the limitations. Nine patients is a cocktail napkin-sized dataset. Phase 1 trials are designed to test safety and find the right dose; they're not built to prove a drug works. An 80% complete response rate looks phenomenal, but small sample sizes can produce numbers that don't hold up at scale. We've all seen promising Phase 1 data melt away in larger trials.

The durability signal (35 months and counting for the longest responder) is genuinely exciting, but this needs confirmation in a randomized, controlled setting with hundreds of patients, not single digits.

A Crowded Race With a Narrow Lane

PeproMene isn't the only company trying to rescue patients after CAR-T failure. Bispecific antibodies like epcoritamab and glofitamab have emerged as the go-to salvage options, with overall response rates around 43% in post-CAR-T patients. Polatuzumab vedotin, an antibody-drug conjugate, has also shown activity in this setting. Even radiation can work for localized relapses.

But those therapies rarely produce durable complete responses in this population. That's where PMB-CT01's early data stands out. A meta-analysis found that non-CD19 CAR-T approaches had the highest response rates among salvage options, with an 80% overall response rate and 56% complete response rate in selected trials. PeproMene's numbers fit right into that sweet spot.

The real question is whether a second CAR-T infusion (with all its manufacturing complexity and cost) can compete practically against off-the-shelf bispecifics that a doctor can order and administer the same week.

What Comes Next

PeproMene needs to do three things to turn this from a promising headline into a viable therapy. First, run a larger trial. Second, prove the durability holds beyond a handful of patients. Third, figure out the commercial path for a small company with limited resources.

Publishing in The Lancet was a smart credibility move; it signals the data passed rigorous peer review. But for the patients running out of options after CAR-T failure, the clock is ticking. The 1-year overall survival rate after CAR-T relapse sits at a brutal 21% in some studies.

For those patients, a therapy that targets a different lock on the same door isn't just interesting science. It might be the only door left.